Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

• Status: Recruiting
• Trial end date: 2023-03-30
• Target enrollment: 0
• Participant gender: All

Summary

Smoking cessation has been shown to improve the effectiveness and reduce the morbidity of tobacco-related cancer treatments. We will identify effective smoking cessation strategies for patients who are receiving treatment for tobacco-related cancer. In this trial, patients' preferences in smoking cessation therapy will be the principal determinant by providers in developing a three component regimen of pharmaceutical therapy, counseling, and nicotine replacement therapy. This study will identify this cohort's preferences for smoking cessation strategies. We will then examine the impact of utilizing patient preferences upon cessation efficacy by directly comparing cessation success in this study with our recently completed study of the same population using the same tobacco treatments which were randomly assigned.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Joseph Valentino, MD
• Treatments: Bupropion; Nicotine; Varenicline

Criteria

Inclusion Criteria:

• newly diagnosed or recurrent tobacco related malignancy

• smoked at least 1 cigarette within 4 weeks of study enrollment

• 10-pack year history of cigarette smoking

• smoked at least 1 cigarette within 1 month of cancer diagnosis

• life expectancy greater than 1 year

Exclusion Criteria:

• allergy to buproprion, varenicline and transdermal medicine

• history of suicide attempt

• hospitalized for psychiatric illness within past 2 years

• history of active or uncontrolled eating disorder

• uncontrolled epilepsy or seizure disorder

• pregnant or lactating

• within 3 months of myocardial infarction

• unstable angina

• uncontrolled hypertension

• serious arrhythmia

• history of taking varenicline or buproprion within one month of enrollment

• concurrent enrollment in tobacco cessation therapy